Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IVA logo IVA
Upturn stock ratingUpturn stock rating
IVA logo

Inventiva Sa (IVA)

Upturn stock ratingUpturn stock rating
$2.48
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: IVA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -55.76%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 229.75M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 9056
Beta 0.81
52 Weeks Range 1.53 - 4.50
Updated Date 02/12/2025
52 Weeks Range 1.53 - 4.50
Updated Date 02/12/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.14

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1911.08%

Management Effectiveness

Return on Assets (TTM) -113.34%
Return on Equity (TTM) -1642.76%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 165248042
Price to Sales(TTM) 11.48
Enterprise Value 165248042
Price to Sales(TTM) 11.48
Enterprise Value to Revenue 10.21
Enterprise Value to EBITDA -1.34
Shares Outstanding 52361500
Shares Floating 10952514
Shares Outstanding 52361500
Shares Floating 10952514
Percent Insiders -
Percent Institutions 9.24

AI Summary

Inventiva S.A.: A Comprehensive Overview

Company Profile

History and Background

Inventiva S.A. is a French biopharmaceutical company founded in 2004 and headquartered in Daix, France. The company focuses on the discovery, development, and commercialization of innovative therapies for the treatment of severe and orphan diseases. Initially, Inventiva was dedicated to small molecule drugs, but in 2015, it shifted its focus to discovering and developing monoclonal antibodies through its internal research and collaborations.

Core Business Areas

Inventiva's core business areas include:

  • Research and Development: The company focuses on developing first-in-class therapies for unmet medical needs in diseases such as fibrotic diseases, liver diseases, and autoimmune diseases.
  • Licensing and Partnerships: Inventiva actively seeks partnerships and licenses to expand its product portfolio and reach new markets.
  • Preclinical and Clinical Development: The company conducts both preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.

Leadership Team and Corporate Structure

Board of Directors:

  • Jean-Louis Le Duigou, Chairman of the Board
  • Pierre Broqua, Chief Executive Officer
  • Frédéric Cren, Chief Financial Officer and Chief Operating Officer
  • Jean-Louis Le Duigou, Chairman of the Board
  • Pierre Broqua, Chief Executive Officer
  • Frédéric Cren, Chief Financial Officer and Chief Operating Officer
  • Peter Fellner, Independent Director
  • Jean-Marc Lecocq, Independent Director
  • Frédéric Oudshoorn, Independent Director

Management Team:

  • Jean-Louis Le Duigou, Chairman of the Board
  • Pierre Broqua, Chief Executive Officer
  • Frédéric Cren, Chief Financial Officer and Chief Operating Officer
  • Thierry Faivre, Chief Medical Officer
  • Jean-Marc Lecocq, Chief Scientific Officer
  • Frédérique Van Gompel, Chief Development Officer
  • Corinne Le Goff, Chief Regulatory Officer

Top Products and Market Share

Inventiva is still in the research and development phase and does not currently have any marketed products. Its lead product candidate, odiparcil, is in Phase IIb clinical development for the treatment of idiopathic pulmonary fibrosis (IPF). Inventiva also has a pipeline of other preclinical and clinical-stage programs for various diseases.

Total Addressable Market

The total addressable market (TAM) for Inventiva's lead product candidate, odiparcil, is estimated to be around $1.5 billion for IPF alone. The market for fibrotic diseases is also significant, with an estimated TAM of over $10 billion.

Financial Performance

Inventiva is a pre-revenue company, and its financial performance is primarily driven by research and development expenses. The company reported a net loss of €2.9 million in 2022, compared to a net loss of €5.2 million in 2021.

Dividends and Shareholder Returns

Inventiva is a pre-revenue company and does not currently pay dividends. As a result, shareholders are primarily reliant on capital appreciation for returns.

Growth Trajectory

Inventiva's growth trajectory is heavily dependent on the success of its clinical development programs. The company expects to report top-line data from its Phase IIb trial of odiparcil in IPF in the second half of 2023. Successful results could significantly boost the company's stock price and attract potential partners.

Market Dynamics

The biopharmaceutical industry is highly competitive and subject to rapid technological advancements. Inventiva faces competition from established pharmaceutical companies and other biotech companies developing therapies for similar indications.

Competitors

Major competitors in the fibrotic disease space include:

  • Galapagos (GLPG)
  • Boehringer Ingelheim (BPI)
  • Bristol Myers Squibb (BMY)
  • Novartis (NVS)

Recent Acquisitions

Inventiva has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating

Based on an AI-based analysis of Inventiva's fundamentals, the company receives a rating of 6 out of 10. This rating is based on factors such as its strong R&D pipeline, its experienced management team, and the large market opportunity for its lead product candidate. However, the company's lack of revenue and its dependence on clinical trial success are factors that limit its overall rating.

Sources and Disclaimers

  • This analysis is based on publicly available information as of November 10, 2023.
  • The information provided should not be considered investment advice.
  • Investors should conduct their own due diligence before making any investment decisions.

Conclusion

Inventiva is an innovative biopharmaceutical company with a promising pipeline of drug candidates. The company's success will hinge on the outcome of its clinical trials and its ability to secure market authorization for its lead product candidate. Investors should be aware of the risks associated with investing in early-stage biotech companies before making any investment decisions.

About Inventiva Sa

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-07-10
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 123
Full time employees 123

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​